Budesonide MMX®: A review of its use in patients with mild to moderate ulcerative colitis

Drugs

Volumn 75, Issue 8, 2015, Pages 879-886

  Hoy, Sheridan M ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BUDESONIDE; ANTIINFLAMMATORY AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; ADD ON THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; MONOTHERAPY; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; RHINOPHARYNGITIS; TREATMENT DURATION; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DELAYED RELEASE FORMULATION; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; HUMANS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84930178465     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0396-8     Document Type: Review

References (22)

1. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965-90.
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501-23 (quiz 24).
3. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713-25.
4. Prantera C, Scribano ML. Budesonide multi-matrix system formulation for treating ulcerative colitis. Expert Opin Pharmacother. 2014;15(6):741-3.
5. Nicholls A, Harris-Collazo R, Huang M, et al. Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. J Int Med Res. 2013;41(2):386-94.
6. Ferring Pharmaceuticals Ltd. Cortiment 9 mg, prolonged release tablets: summary of product characteristics. 2014. http://www.mhra.gov.uk/spc-pil/index.htm. Accessed 13 Mar 2015.
7. Santarus Inc. UCERIS (budesonide) extended release tablets, for oral use: prescribing information. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 13 Mar 2015.
8. Salix Pharmaceuticals Inc. UCERIS (budesonide) rectal foam: prescribing information. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 13 Mar 2015.
9. ® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis. 2010;4(2):153-60.
10. Brunner M, Ziegler S, Di Stefano AFD, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 2006;61(1):31-8.
11. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143(5):1218-26.e2.
12. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63(3):433-41.
13. Rubin DT, Cohen RD, Sandborn W, et al. Budesonide MMX® 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-ASAs [abstract no. O-001]. Inflamm Bowel Dis. 2014;20(Suppl 1).
14. Sandborn WJ, Danese S, D'Haens G, et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015;41(5):409-18.
15. US National Institutes of Health. ClinicalTrials.gov. 2014. http://clinicaltrials.gov/. Accessed 13 Mar 2015.
16. Ferring Pharmaceuticals Ltd. CORTIMENT®MMX®, a new treatment for ulcerative colitis, receives European approval. 2014. http://www.ferring.com/en/media/press-releases/2014/cortiment-european-approval-20-oct-14/. Accessed 13 Mar 2015.
17. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991-1030.
18. Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39(10):1095-103.
19. Ferring BV. Cortiment 9 mg, prolonged release tablets: summary of product characteristics. 2013. http://www.cbg-meb.nl/cbg/nl. Accessed 13 Mar 2015.
20. Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;10:CD007698.
21. Travis S, Danese S, Ballard ED, et al. Safety analysis of budesonide MMx 6 mg used for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study [abstract no. Su2088]. Gastroenterology. 2012;142(5 Suppl 1):S-566-7.
22. Travis S, Danese S, Ballard ED, et al. Effect of long-term budesonide MMx 6 mg use on bone mineral density in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study [abstract no. Su2087 ]. Gastroenterology. 2012;142(5 Suppl 1):S-566.